Arbutus Biopharma (ABUS) Reports In-Line Q3 EPS; Cash and Cash Equivalents of 151.9M
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- US stock futures fall as fading Iran peace prospects drive up oil, yields
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Wall Street indexes slip as oil prices rise, retail results awaited
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Trump threatens to bomb Oman over Iran stance
- H.C. Wainwright Reiterates Buy Rating on Soluna (SLNH)
Arbutus Reports Third Quarter 2021 Financial Results and Provides Corporate Update
November 4, 2021 7:30 AM EDTÂ On-track for multiple data readouts of AB-729 and AB-836 in Q4 2021
        First patient dosed in Phase 2a clinical trial combining AB-729, Peg-IFN-2a and nucleos(t)ide analog (NA) therapy
        On-track to initiate several proof-of-concept Phase 2a clinical trials with AB-729 as a cornerstone agent in combination with other approved or investigational compounds
        Commenced IND enabling studies for Arbutus oral PD-L1 program
Cash runway guidance extended into the second quarter of 2023
Conference call and webcast scheduled today at... More
